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Abstract
Background:  Mutations within the leucine-rich repeat kinase 2 (LRRK2) gene account for a
significant proportion of autosomal-dominant and some late-onset sporadic Parkinson's disease.
Elucidation of LRRK2 protein function in health and disease provides an opportunity for
deciphering molecular pathways important in neurodegeneration. In mammals, LRRK1 and LRRK2
protein comprise a unique family encoding a GTPase domain that controls intrinsic kinase activity.
The expression profiles of the murine LRRK proteins have not been fully described and
insufficiently characterized antibodies have produced conflicting results in the literature.
Results: Herein, we comprehensively evaluate twenty-one commercially available antibodies to
the LRRK2 protein using mouse LRRK2 and human LRRK2 expression vectors, wild-type and LRRK2-
null mouse brain lysates and human brain lysates. Eleven antibodies detect over-expressed human
LRRK2 while four antibodies detect endogenous human LRRK2. In contrast, two antibodies
recognize over-expressed mouse LRRK2 and one antibody detected endogenous mouse LRRK2.
LRRK2 protein resides in both soluble and detergent soluble protein fractions. LRRK2 and the
related LRRK1 genes encode low levels of expressed mRNA species corresponding to low levels of
protein both during development and in adulthood with largely redundant expression profiles.
Conclusion: Despite previously published results, commercially available antibodies generally fail
to recognize endogenous mouse LRRK2 protein; however, several antibodies retain the ability to
detect over-expressed mouse LRRK2 protein. Over half of the commercially available antibodies
tested detect over-expressed human LRRK2 protein and some have sufficient specificity to detect
endogenous LRRK2 in human brain. The mammalian LRRK proteins are developmentally regulated
in several tissues and coordinated expression suggest possible redundancy in the function between
LRRK1 and LRRK2.
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Background
Mutations in the leucine-rich repeat kinase 2 (LRRK2,
OMIM 609007) gene are the most common known cause
for sporadic and familial Parkinson's Disease (PD) [1-4].
The most frequent mutation in North America and
Europe is a glycine to serine substitution at residue 2019
(G2019S) in the LRRK2 protein which accounts for up to
10% in familial cases and up to 2% in sporadic cases [5-
9]. Frequencies of LRRK2  mutations in PD cases are
reported as high as 40% in North Africans and Ashkenazi
Jews [10,11], but since penetrance of the mutation in 80
year old carriers may be as low as 30% with standard diag-
nosis [12] the discrimination between familial and spo-
radic disease becomes difficult [13]. LRRK2  mutation
carriers present with similar clinical and neurochemical
features to sporadic disease, and with only few exceptions,
present with typical Lewy body pathology [14,15].
Due to the unprecedented frequency of mutations in
LRRK2 occurring in PD, a number of laboratories have
embarked on the development of LRRK2-null and LRRK2
transgenic animals. In multiple-tissue Northern blots,
LRRK2 is nearly constitutively expressed but the timing of
expression has not been described nor the profile of the
related LRRK1 gene [1,2,16]. Given the sequence similar-
ity between LRRK1  and LRRK2, a complete expression
profile may indicate whether redundancy in function
could mask a phenotype in transgenic and knock-out ani-
mals. In addition, inappropriate expression in transgenic
animals due to off-tissue expression or abnormal develop-
mental expression may initiate undesirable phenotypes
and reduce the utility as a PD model. To provide the com-
plete expression profile of LRRK2 and LRRK1, we utilize
quantitative PCR, Northern blot and Western blot experi-
ments to track levels of expression.
The 2527 amino acid multi-domain protein kinase LRRK2
is associated with membranes in rodent brain and is
present in tissues relevant to PD in human and rodent
brain [17-20]. Some studies suggest the presence of
LRRK2 protein in disease-associated aggregations such as
Lewy bodies and Lewy neurites, using different antibodies
against human LRRK2 [21-23]. To aid the neurodegenera-
tion research community we present a detailed character-
ization of twenty-one commercially available antibodies
to mouse and human LRRK2 purported as specific to the
280 kDa protein.
Results
LRRK2 is present in both freely soluble and SDS-soluble 
fractions of mouse brain lysate as determined by antibody 
JH5514
Published literature to date suggests many commercially
available antibodies raised against peptides derived from
human LRRK2 sequence detect a protein of approximately
280 kDa in size in mouse or human tissue and/or cell
lines [21-28]. To confirm whether these antibodies detect
mouse LRRK2 or cross-reactive protein species unrelated
to LRRK2 migrating near 280 kDa, we performed immu-
noblot analyses of the various antibodies in wild type
mice and LRRK2 knock-out mice in which exons 39 and
40 are disrupted (S. Biskup, M. Sasaski, V.L. Dawson and
T.M. Dawson, personal observation) (Figure 1). Our pre-
viously characterized antibody JH5514 recognizes human
over-expressed and endogenous LRRK2 protein in mouse
and humans with minimal cross-reactivity with other pro-
tein species and LRRK2 immunoreactivity is absent in
LRRK2 KO mice (Figure 1A). No endogenous LRRK2 can
be detected in HEK-293T cells even with long exposures
and high antibody concentrations (Figure 1A and data not
shown). Our validated antibody JH5514 does not detect a
protein of the appropriate size, determined through align-
ment with recombinant LRRK2 protein, in any tested cell
line lysate including human embryonic kidney (HEK-
293T) cells, human neuroblastoma (SH-SY5Y) cells,
human neuroblastoma (BE(2)-M17) cells and rat adrenal
(PC-12) cells (data not shown). Several of these cell lines,
including HEK-293T and SH-SY5Y express a low level of
LRRK2 mRNA compared with brain tissue suggesting
post-transcriptional regulation (data not shown).
With a series of different extraction buffers for mouse
brain using LRRK2-null brain tissue as a control, we show
that membrane disruption through simple mechanical
homogenization of brain tissue in PBS (low salt buffer) or
in high salt buffer is sufficient to extract the majority of
mouse LRRK2 that can be detected by Western Blot (Fig-
ure 1A). Mouse LRRK2 protein is also detected in rela-
tively insoluble fractions only resolved through the
addition of 1% SDS buffer. Incubation of lysate samples
supplemented with 1× Laemmli sample buffer for ten
minutes at temperatures above room temperature led to a
loss of recoverable levels of LRRK2 (Figure 1B). This phe-
nomenon is apparently not due to an interaction with
plastic disposables since siliconized tubes and tips had no
effect. Supplementation of the sample buffer lysate solu-
tion with either 4 M urea or 5% Formic acid (FA) after
incubation for ten minutes at 90°C resulted in a signifi-
cant recovery of LRRK2 protein levels, suggesting that
LRRK2 may form SDS-resistant insoluble aggregates with
elevated temperatures (Figure 1B).
Commercially available antibodies that recognize over-
expressed and endogenous mouse LRRK2
Using a panel of over-expressed mouse LRRK2 (mLRRK2)
versus empty vector transfected HEK-293T cells in combi-
nation with LRRK2-null versus wild-type mouse brain tis-
sue, we tested twenty-one commercially available LRRK2
antibodies to determine specificity. Most of the antibodies
cannot detect over-expressed mLRRK2 or endogenousBMC Neuroscience 2007, 8:102 http://www.biomedcentral.com/1471-2202/8/102
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Biochemical characterization of LRRK2 and testing of LRRK2 antibodies on mouse tissue Figure 1
Biochemical characterization of LRRK2 and testing of LRRK2 antibodies on mouse tissue. A) Over-expressed 
mouse LRRK2 detected by JH5514 versus empty vector transfected HEK-293T cells. Whole mouse brain was mechanically 
homogenized in either PBS (low salt buffer), high salt buffer (PBS supplemented to 600 mM NaCl), 1% Triton X-100 (in PBS), 
1% SDS (in PBS) or RIPA (1% SDS, 1% sodium deoxycholate, 1% NP-40). All buffers contained complete protease inhibitors 
(Roche). A knockout mouse brain is homogenized in PBS (low salt) alone and shown as control. B) Lysates derived from HEK-
293T cells transfected with mLRRK2 plasmids were incubated in 1 × Laemmli sample buffer at the indicated temperatures for 
10 minutes and then analyzed by SDS-PAGE. Plasticware used to process the protein samples were either siliconized or left 
untreated. Indicated samples were supplemented with 5% Formic acid (FA) or 4M urea after 10 minute incubation at the indi-
cated temperature. C) LRRK2 antibodies Novus 267 and 268, Abgent AP7099b, and Chemicon (AB9682) in addition to Alexis 
(AT106) and Cell Signaling (2567) were tested on over-expressed mouse LRRK2 protein and wildtype and LRRK2-deficient 
mouse brain homogenized in PBS alone. All antibodies recognize cross-reactive bands near the expected size of LRRK2. An 
arrow denotes the position of LRRK2 in the Alexis (AT106) blot. All antibodies were tested on at least two independent mem-
branes and lysates using optimized exposure conditions with similar results.
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wild-type mLRRK2 protein (For a summary, see Table 1).
For example, the antibodies Novus 267, Novus 268,
Abgent AP7099b do not have the sufficient specificity to
detect mLRRK2, either over-expressed or endogenous
using standard blotting conditions (Figure 1C). Of note,
antibody AP7099b from Abgent was raised against a pep-
tide identical between mouse and human. Typical for the
majority of antibodies tested here, cross-reactive species
near the molecular weight of LRRK2 protein confound the
interpretation of blots when appropriate controls such as
Table 1: Summary of antibodies tested on Western Blot
Antibody Overexpressed 
mLRRK2
Overexpressed 
hLRRK2
Endogenous 
mLRRK2
Endogenous 
hLRRK2
Peptide Location
Abgent AP7099a - - - - N/A
Abgent AP7099b - - - - (LRR, AA 1246–1265, 100% identity)
H: WSRVEKLHLSHNKLKEIPPE
M: WSRVEKLHLSHNKLKEIPPE
Abgent AP7099c - - - - (N-Term, around L229)
H: EEIVLHVLHCLHSLAIPCNNVEVLMSGNVR
M: KEIVYHVLCCLHSLAVTCSNVEVLMSGNVR
Abgent AP7099d - - - - (N-Term, around E285)
H: VSCCLLHRLTLGNFFNILVLNEVHEFVVKA
M: VSCSLFQKLTLGNFFNILVLNEVHVFVVKA
Abgent AP7099e - + - + (N-Term, around E519)
H: RAILHFIVPGMPEESREDTEFHHKLNMVKK
M: RAILHFVVPGLLEESRE..DSQCRPNVLRK
Abgent AP7099f - + - - (N-Term, around L893)
H: AQSDDLDSEGSEGSFLVKKKSNSISVGEFY
M: GQSDDLDSEGSESSFLVKRKSNSISVGEVY
Abgent AP7099g - + - - (N-Term, around L899)
H: AQSDDLDSEGSEGSFLVKKKSNSISVGEFY
M: GQSDDLDSEGSESSFLVKRKSNSISVGEVY
Abgent AP7099h - + - - (N-Term, around L955)
H: IFDHEDLLKRKRKILSSDDSLRSSKLQSHM
M: VFDHEDLLRRKRKILSSDESLRSSRLPSHM
Abgent AP7099i - - - - (C-Term, around C2354)
H: STERNVMWGGCGTKIFSFSNDFTIQKLIET
M: SSERHITWGGCGTKVFSFSNDFTIQKLIET
Abgent AP7099j - - - - (C-Term, around K2402)
H: CVHFLREVMVKENKESKHKMSYSGRVKTLC
M: CVHFLKEVMVKLNKESKHQLSYSGRVKALC
Abgent AP7099k - - - - (C-Term, around Y2475)
H: 
MTAQLGSLKNVMLVLGYNRKNTEGTQKQKE
M: ATAQLGSLKNVMLVLGYKRKSTEGIQEQKE
Abgent AM7099a - - - - (monoclonal) N/A
Abgent AM7099b - - - - (monoclonal) N/A
Abcam 27482 - + - - N/A
Abcam 19906 - - - - N/A
Novus Biological 267 - + - + (N-Term, AA 920–945)
H: SNSISVGEFYRDAVLQRCSPNLQRHS
M: SNSISVGEVYRDLALQRYSPNAQRHS
Novus Biological 268 - + - + (C-Term, AA 2500–2527)
H: INLPHEVQNLEKHIEVRKELAEKMRRTSVE
M: LNLPHEVQNLEKHIEVRTELADKMRKTSVE
Chemicon AB9682 - + - - N/A, synthetic peptide from rat
Chemicon AB9704 - + - - N/A
Alexis (AT106) + + + + (AA 1838–2133)
Cell Signaling 2567 + + - - (C-Term, G2090)
H: FPNEFDELEIQGKLPDPVKEYGCAPWPMVE
M: FPNEFDELAIQGKLPDPVKEYGCAPWPMVE
JH5514 + + + + (C-Term, AA 2500–2515), 100% identity
H: INLPHEVQNLEKHIE
M: LNLPHEVQNLEKHIE
Summary of the results of commercially available antibodies against LRRK2 tested on Western Blot. A (+) denotes antibodies that produce a 
discernable band specific to LRRK2 protein. A (-) denotes antibodies unable to detect a band specific to LRRK2 protein. Antibodies were designed 
against the human sequence unless otherwise indicated.BMC Neuroscience 2007, 8:102 http://www.biomedcentral.com/1471-2202/8/102
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LRRK2-null brain lysate are not included. With very high
concentrations and exposure times, many cross reactive
bands appear near the expected size of LRRK2 protein but
none are changed in the LRRK2-null brain lysate for all
commercially available antibodies with the exception of
the Alexis (AT106) antibody, which recognizes a faint
band immediately under a prominent cross-reactive pro-
tein species near 280 kDa (Figure 1C). Other antibodies
capable of detecting over-expressed mLRRK2 in HEK 293T
cells such as the Cell Signaling (2567) and Chemicon
(ab9682) antibodies recognize cross-reactive protein spe-
cies that presumably mask endogenous mLRRK2 protein
due to the insufficient separation afforded by commer-
cially available gradient mini-gels.
Commercially available antibodies that recognize over-
expressed and endogenous human LRRK2
All antibodies were additionally tested on human over-
expressed LRRK2 versus empty vector transfected HEK-
293T cells (Table 1). Figure 2A shows the panel of anti-
bodies capable of detecting over-expressed human LRRK2
(Novus 267, Novus 268, Abgent AP7099e, AP7099f,
AP7099g, AP7099h, Abcam 27482 and Cell Signaling
2567). We tested antibodies capable of robustly detecting
over-expressed human LRRK2 protein (Novus 267, Novus
268, Abgent AP7099e, AP7099f, AP7099g, AP7099h,
Abcam 27482) using human brain lysate derived from
fresh-frozen samples of human temporal lobe. In situ
hybridization analyses have previously demonstrated
LRRK2 mRNA is at the highest levels in the cortex and
striatum and we would expect significant quantities of
LRRK2 protein in the temporal lobe [16,18,29-32]. Novus
267, Novus 268 and AP7099e all have sufficient specifi-
city to detect human LRRK2 based on their ability to
resolve a band of the predicted molecular weight of
LRRK2 with identical solubility profiles (Figure 2B).
Novus 268 and AP7099e are shown in comparison with
our in-house antibody JH5514 (Figure 2B). Using gel sys-
tems other than Tris-Glycine such as Tris-Acetate or Bis-
Tris gels causes a dramatically different migration of
LRRK2 protein with respect to protein markers, with
migration near 240 kDa in Tris-Acetate gels (data not
shown).
We visualized LRRK2 protein by Western blot in human
brain lysates derived from tissue with minimal delay in
processing (fresh frozen brain samples) and have been
unsuccessful in detecting LRRK2 protein from the vast
majority of archived frozen brain samples that correspond
to typical post-mortem delays (4–24 hours) (data not
shown). This may be due to a high rate of degradation or
processes that otherwise render LRRK2 inaccessible to
detection by immunoblotting due to typical post-mortem
delay in most human tissue samples available. We have
not observed significant decay in LRRK2 protein within
protein lysate when stored at -20 or -80 degrees or dra-
matic loss of LRRK2 due to freeze/thaw cycles (data not
shown).
LRRK1 and LRRK2 expression in development and 
adulthood
Many invertebrate organisms such as Drosophila and
lower vertebrate organisms such as Fugu and Zebrafish
possess only a single LRRK gene, suggesting mammalian
LRRK1 and LRRK2 protein diverged from a single founder
[33].  LRRK-like proteins and orthologues extend well
beyond complex invertebrates into even simple single-
celled eukaryotic organisms [34], suggesting a fundamen-
tal albeit unknown role for the LRRK family of proteins in
mammals. Northern blot analysis has previously shown a
broad distribution of LRRK2 mRNA in the brain and other
organs in humans [1,2]. In order to better understand the
regulation of LRRK2 expression we measured LRRK1 and
LRRK2 mRNA in multiple organs in neonatal and adult
mice (Figure 3A, B). We observed statistically identical lev-
els of LRRK1 and LRRK2 mRNA in the lung, heart, skeletal
muscle and lymph node (Figure 3B). LRRK2  mRNA is
more abundant in kidney and brain tissue, whereas
LRRK1 mRNA is more abundant in the gut.
Using Northern (whole mouse embryo) and Western
(whole brain lysate) blotting we show that LRRK2 does
not have an expression profile typical of a gene important
during early development (Figure 4A,B). mRNA levels
measured from whole mouse embryos show that LRRK2
expression increases from embryonic day 15 to day 17
(Figure 4A). Given the large increase in expression of
LRRK2 during the latest stages of development, we created
a panel of cDNA derived from developing mouse organs,
including brain, lung, heart and liver, at various stages of
development. We then went on to compare LRRK1 and
LRRK2 levels using quantitative RT-PCR and observed a
dynamic expression profile that distinguishes LRRK1 from
LRRK2. LRRK2 most dramatically increases in lung and
kidney between E15.5 and E19.5 partially accounting for
the results of the whole-embryo Northern blot. Surpris-
ingly, LRRK2 mRNA is constitutively expressed early in
development of the brain and does not substantially
increase upon cell maturation as might be expected by the
Northern blot of whole embryo (Figure 4C). LRRK1 levels
spike at E15.5 in the brain then decrease below LRRK2 lev-
els and remain low with respect to LRRK2  throughout
adulthood. In other organs such as the lung and liver,
LRRK2 dramatically increases in the latest stages of devel-
opment in contrast to the more constitutive expression in
the heart where LRRK1 and LRRK2 are nearly identically
expressed both in development and throughout adult-
hood.BMC Neuroscience 2007, 8:102 http://www.biomedcentral.com/1471-2202/8/102
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Testing of LRRK2 antibodies on human tissue Figure 2
Testing of LRRK2 antibodies on human tissue. A) Antibodies able to detect over-expressed human LRRK2 protein. B) 
Fresh frozen tissue samples from the human temporal lobe (Htl) is subjected to different extraction buffers as in figure legend 
1A. Novus 267, Novus 268, Abgent AP7099e and JH5514 have sufficient specificity to detect endogenous human LRRK2. All 
antibodies were tested on at least two independent membranes and lysates using optimized exposure conditions with similar 
results.
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Discussion
The function of LRRK proteins in mammals remains enig-
matic yet strong evolutionary conservation suggests
important roles. Besides obvious interest in understand-
ing the only proteins in the mammalian proteome encod-
ing both a kinase and GTPase domain, the striking
association between LRRK2 and PD further justifies the
speedy discovery of LRRK2 protein function in cells.
Within the present study we show that several commer-
cially available antibodies recognize endogenous human
LRRK2 protein but no tested commercially available anti-
body can efficiently resolve mouse LRRK2 protein despite
a number of reports that did not have the benefit of
LRRK2-null mice. To the contrary, more abundant cross-
reactive species near or at the molecular weight of
mLRRK2 protein are detected by most commercially avail-
able antibodies as shown for the human specific Novus
antibodies and the Abgent antibody AP7099b. Cross-reac-
LRRK1 and LRRK2 mRNA levels in development and adulthood Figure 3
LRRK1 and LRRK2 mRNA levels in development and adulthood. A) Neonatal LRRK1 and LRRK2 mRNA levels. Rela-
tive LRRK expression was calculated by normalization to TBP (TATA binding protein) within each tissue sample using the delta 
delta CT method. Similar results were obtained with internal normalization to GAPDH. Error bars represent standard error 
mean derived from two each independently analyzed male and female 14 day old CD-1 mice B) LRRK1 and LRRK2 mRNA levels 
in adult mouse tissues as normalized to TBP. Similar results were obtained with normalization to GAPDH. Error bars represent 
standard error mean independently derived from two each female and male 3 month old CD-1 mice.
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LRRK1 and LRRK2 mRNA levels in development and adulthood Figure 4
LRRK1 and LRRK2 mRNA levels in development and adulthood. A) Northern blot analysis of different embryonic 
stages (whole mouse embryo) using a LRRK2 specific riboprobe. B) LRRK2 protein can be detected by JH5514 in whole brain 
lysates on E17 and throughout post-natal development C) Relative LRRK1 and LRRK2 mRNA levels in direct comparison calcu-
lated from whole brain, lung, heart and liver during embryonic stages E11.5 to E19.5, with internal normalization to TBP tran-
script. Error bars represent standard error mean independently derived from a total of four CD-1 embryos at the indicated 
age.
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tive species likely mask endogenous mLRRK2 protein in
the case of antibodies from Cell Signaling and Chemicon.
However, both antibodies are capable of detecting over-
expressed mouse protein. The Alexis antibody detects
over-expressed mouse protein and endogenous mouse
protein that migrates slightly below cross-reactive species.
It may be possible with additional purification steps,
blocking optimization, extraction optimization and
improved washing and blotting conditions that some of
the antibodies tested here will prove useful in the future.
In all tissues, LRRK1 and LRRK2 mRNA is rare compared
to even nominally expressed transcripts such as TATA
binding protein (TBP) and cyclophilin-A, both used here in
addition to GAPDH as normalization controls. The com-
bination of a poorly expressed transcript with an appar-
ently unstable protein of above-average size creates a
worst case scenario for routine detection of endogenous
protein by Western blotting and immunocytochemistry
despite the high solubility of LRRK2 protein.
We describe cloning of mouse LRRK2 into expression vec-
tors and the expression profile of LRRK1 and LRRK2 in the
developing and adult mouse. Mouse LRRK2 expression
increases from embryonic day 15 to day 17 and continues
through adulthood. In some organs, such as the brain,
LRRK2 expression apparently increases to a more nominal
extent at earlier time points. We have been unable to
detect LRRK2 protein in the brain before embryonic day
17 using the western blotting conditions and protein
extraction protocols described here. LRRK1 and LRRK2
expression overlaps in all tissues used in this study (whole
brain, eye, lung, skeletal muscle, smooth muscle, thymus,
lymph node, heart, stomach, liver, kidney and gut), and in
some tissues expression levels are identical. LRRK2 expres-
sion levels are particularly high in embryonic and adult
lung and kidney. As kinase enzymes, LRRK protein may
target tissue specific substrates for phosphorylation. It is
possible that LRRK protein is so critical to cell function
that the protein has diverged into two related proteins to
provide a protective measure of redundancy in function.
Conclusion
Knowledge about localization, function and substrates of
LRRK1 and 2 protein will help clarify LRRK2 associated
disease. We characterized twenty-one commercially avail-
able antibodies against LRRK2 protein and describe the
biochemical properties of mouse and human LRRK2 pro-
teins with regards to solubility and expression. The impor-
tance of LRRK1 and LRRK2 for mouse development and
adult mice in different tissues is actively pursed by many
research groups. LRRK1  and  LRRK2  are comparably
expressed in most tissues with stable expression in adult-
hood but dynamic expression during development, with
a general trend towards increased expression during orga-
nogenesis and maturation.
Methods
Antibody production and western blotting
Affinity-purified rabbit polyclonal antibodies were gener-
ated to LRRK2 protein as described previously [17]. Pro-
tein extracts from adult mouse and fresh frozen tissue
samples from the human temporal lobe were prepared as
described [17] and Western blot analysis (6% SDS-PAGE
gels) was conducted as previously described for LRRK2
[19]. Human tissue samples were obtained from human
brain temporal lobe resections snap-frozen immediately
after removal and stored at -80°C until homogenization.
Briefly: whole mouse brain or temporal human brain was
mechanically homogenized in either PBS (low salt
buffer), high salt buffer (PBS supplemented to 600 mM
NaCl), 1% Triton X-100 (in PBS), 1% SDS (in PBS) or
RIPA (1% SDS, 1% sodium deoxycholate, 1% NP-40). All
buffers contained complete protease inhibitors (Roche).
Antibodies were diluted 1:1000 in TBS-T containing 5%
skimmed milk if not otherwise indicated. Incubation with
primary antibodies was performed overnight. LRRK2
knockout mice were generated by disruption of exons 39
and 40 of the mouse LRRK2 gene (S. Biskup, M. Sasaki,
V.L. Dawson and T.M. Dawson, personal observation).
Wild-type, heterozygote and knockout LRRK2 mice were
generated by crossbreeding of germline chimaeras to
C57BL/6J mice. Protein extracts from mouse and fresh fro-
zen tissue samples from the human temporal lobe were
processed for Western blotting with LRRK2 antibodies as
described above. LRRK2 antibodies were obtained from
Abgent, Novus Biologicals, Abcam, Chemicon, Alexis and
Cell Signaling.
Generation of human and mouse LRRK2 constructs
The generation of human LRRK2 constructs has been pre-
viously described [19,35].
The full-length cDNA of mouse LRRK2  was amplified
from a Marathon-Ready mouse embryo 17d cDNA library
(BD Biosciences). Using nested primers based on mouse
LRRK2  (GenBank accession number NM_025730) and
PfuTurbo hotstart DNA polymerase (Stratagene) according
to the manufacturer's protocol, two overlapping frag-
ments from exons 1–28 (~3.9 kb) and exons 15–51 (~5.9
kb) were generated. The first part of the LRRK2 cDNA
(exons 1–28) was cloned in pBluescript SK+ (Stratagene)
(KpnI/NotI) and sequenced with an ABI Prism Big Dye Ter-
minator cycle sequencing kit on an ABI Prism 3730 DNA
analyzer (Applied Biosystems). To generate a full-length
LRRK2 clone the second part of LRRK2 (exons 15–51) was
cloned in the pBluescript plasmid already containing one
part of LRRK2 (NdeI/NotI). The entire open reading frame
of LRRK2 (7584 bp) was confirmed by sequencing.BMC Neuroscience 2007, 8:102 http://www.biomedcentral.com/1471-2202/8/102
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Northern blotting
Whole mouse embryonic membranes were purchased
from Clontech. Membranes were hybridized overnight at
65°C with a biotinylated antisense riboprobe synthesized
using the MAXIscript in vitro transcription kit (Ambion)
from a PCR-amplified DNA template with incorporated
T7 promoter, and washed with 2 × SSC/1% SDS and then
0.1 × SSC/0.1% SDS at 65°C. Filters were visualized by
incubation with streptavidin-alkaline phosphatase and
chemiluminescence using the BrightStar BioDetect kit
(Ambion). The riboprobe sequence for LRRK2  corre-
sponds to nucleotide positions 4292 to 4813 of LRRK2
cDNA. PCR primers used were: forward 5'-TGAAGCCTT-
GGCTCTTCAAT-3' and reverse 5'-TAATACGACTCACTAT-
AGGTACAAAGCCACTTGGGTTCC-3' with bold
nucleotides representing the T7 promoter priming site.
Quantitative reverse-transcription PCR
RNA was isolated from embryonic and adult CD-1 mice
(Charles Rivers) via mechanical homogenization and
extraction in TriZOL and both cleaned and concentrated
using a commercially available kit (Qiagen RNEasy Micro;
Qiagen). Reverse transcription was performed using the
Applied Biosystems High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems); cDNA concentrations
were determined with a Nanodrop spectrophotometer
(Nanodrop Technologies) prior to PCR. cDNA samples
underwent absolute quantitative real-time PCR on the
9700HT instrument (Applied Biosystems) under the
default 40-cycle program. TaqMan gene expression assays
were purchased from Applied Biosystems, including
LRRK1 and LRRK2 expression assays (assay Mm0481934
and Mm00713303), TBP (assay Mm00446973_m1),
cyclophilin A (Mm02342429_g1) and GAPDH
(4352932E). For each amplicon, PCR efficiency was esti-
mated near 1.0 by serial dilutions of cDNA. Relative quan-
tities of mRNA were estimated using the delta delta CT
method.
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